NeoStem's subsidiary acquires NEW manufacturing client.

8:04AM Neostem subsidiary, Progenitor Cell Therapy, enters into a cell therapy manufacturing services agreement with Adaptimmune ( NBS ) 0.63 : Co announces its subsidiary, Progenitor Cell Therapy, together with Adaptimmune Limited and Adaptimmune, announced today a Services Agreement under which PCT will provide services to support Adaptimmune's NYESO-1c259-T cell therapy product being developed for multiple oncology indications. PCT's services will include the transfer and qualification of Adaptimmune's manufacturing process for its NYESO-1c259-T cell therapy product candidate at PCT's facility in Allendale, New Jersey and subsequent manufacturing of the product for Adaptimmune's clinical trials.